Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?

Cleveland Clinic Journal of Medicine

Volumn 77, Issue 8, 2010, Pages 503-505

  Olansky, Leann ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; INCRETIN;

ACUTE DISEASE; ADULT; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PANCREATITIS; RISK; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; YOUNG ADULT;

ACUTE DISEASE; ADULT; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; PANCREATITIS; RISK; YOUNG ADULT;

EID: 77956541435     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.77a.09167     Document Type: Note

References (14)

1. Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an update. J Clin Gastroenterol 2005; 39:709-716.
2. Blomgren KB, Sundström A, Steineck G, Wiholm BE. Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis. Diabetes Care 2002; 25:298-302.
3. US Food and Drug Administration. Information for healthcare professionals: exenatide (marketed as Byetta)-8/2008 update. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm. Accessed July 1, 2010.
4. US Food and Drug Administration. Information for healthcare professionals-acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafety InformationforHeathcareProfessionals/ucm183764.htm. Accessed July 1, 2010.
5. Forsmark CE, Baillie J; AGA Institute Clinical Practice and Economics Committee; AGA Institute Governing Board. AGA Institute technical review on acute pancreatitis. Gastroenterology 2007; 132:2022-2044.
6. Pagliarulo M, Fornari F, Fraquelli M, et al. Gallstone disease and related risk factors in a large cohort of diabetic patients. Dig Liver Dis 2004; 36:130-134.
7. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001; 161:1581-1586.
8. Frulloni L, Lunardi C, Simone R, et al. Identification of a novel antibody associated with autoimmune pancreatitis. N Engl J Med 2009; 361:2135-2142.
9. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009; 32:834-838.
10. Whitcomb DC. Clinical practice. Acute pancreatitis. N Engl J Med 2006; 354:2142-2150.
11. Data on file, Amylin Pharmaceuticals, Inc. and Eli Lilly.
12. Dore DD, Seeger JD, Arnold Chan K. Use of a claimsbased active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009; 25:1019-1027.
13. US Food and Drug Administration. Controlled Phase 2b/3 Pooled Population-Day 120 Update. http://www. fda.gov/downloads/AdvisoryCommittees/Committees-MeetingMaterials/Drugs/EndocrinologicandMetabolic-DrugsAdvisoryCommittee/UCM149589. Accessed July 4, 2010.
14. US Food and Drug Administration. Questions and answers-safety requirements for Victoza (liraglutide). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug-SafetyInformationforPatientsandProviders/ucm198543.htm. Accessed July 4, 2010.